MGNX Jan 2025 22.500 call
| Previous close | 7.00 |
| Open | 7.00 |
| Bid | 1.90 |
| Ask | 3.80 |
| Strike | 22.50 |
| Expiry date | 2025-01-17 |
| Day's range | 7.00 - 7.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireMacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., P
Simply Wall St.Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago
This month, we saw the MacroGenics, Inc. ( NASDAQ:MGNX ) up an impressive 37%. But that doesn't change the fact that...
- GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will parti
